Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Breast cancer is not only the leading cause of cancer in women, but also the leading cause of cancer deaths in women. Estrogen receptor-positive and HER2-negative breast cancer is the most prevalent breast cancer subtype. Endocrine therapy is the mainstay of treatment; however, due to the varied nature of the disease, development of resistance to this therapeutic approach is very common in the metastatic setting. The purpose of this study is to see whether the effectiveness of elacestrant can be enhanced by combining it with a targeted agent such as a CDK4/6 inhibitor to treat patients with ER+/HER2- or metastatic breast cancer with prior exposure to a CDK4/6 inhibitor.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak piersi potwierdzony badaniem histologicznym lub cytologicznym jako ER-dodatni i HER2-ujemny.
- •Potwierdzona mutacja genu ESR1 (informacja z historii leczenia pacjenta).
- •Przynajmniej jedna widoczna zmiana nowotworowa (w ciele lub w kościach) do zmierzenia.
- •Przynajmniej dwa wcześniejsze leczenia hormonalne w chorobie przerzutowej, w tym inhibitor CDK4/6.
- •Pacjent(ka) ma 18 lat lub więcej.
- •Ogólny stan zdrowia pacjenta pozwala na codzienne funkcjonowanie (status ECOG 0 lub 1).
- •Dobre wyniki badań krwi wskazujące na prawidłową pracę narządów i szpiku kostnego.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 2, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (3)
Northwestern University
Chicago, United States
Rush University Medical Center
Chicago, United States
University of Chicago
Chicago, United States
Trial contact
Study Coordinator
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.